Search research articles
Contact Us
Filters
Showing results (41-50 of 45) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 45 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 19, 2010
Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS
Arnaud Pigneux, Jean-Luc Harousseau, Francis Witz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 11, 2013
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease
Philippe Rousselot, Aude Charbonnier, Pascale Cony-Makhoul, et al.
The New England Journal of Medicine
|
March 15, 2003
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Stephen G O'Brien, François Guilhot, Richard A Larson, et al.
Journal of the National Cancer Institute
|
March 23, 2011
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib
Carlo Gambacorti-Passerini, Laura Antolini, François-Xavier Mahon, et al.
The New England Journal of Medicine
|
December 8, 2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J Druker, François Guilhot, Stephen G O'Brien, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 45) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 45 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 19, 2010
Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS
Arnaud Pigneux, Jean-Luc Harousseau, Francis Witz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 11, 2013
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease
Philippe Rousselot, Aude Charbonnier, Pascale Cony-Makhoul, et al.
The New England Journal of Medicine
|
March 15, 2003
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Stephen G O'Brien, François Guilhot, Richard A Larson, et al.
Journal of the National Cancer Institute
|
March 23, 2011
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib
Carlo Gambacorti-Passerini, Laura Antolini, François-Xavier Mahon, et al.
The New England Journal of Medicine
|
December 8, 2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J Druker, François Guilhot, Stephen G O'Brien, et al.
Page
of 5